RxDoctor Payments Data

Daniel Everts, OD

Optometrist · Waupaca, WINPI 1811968878

Payments from drug & device makers

$2,641in general payments, 2019–2025

Across 29 payments — averaging $91.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Coopervision Inc.$933
  • Bausch & Lomb Americas Inc.$54
  • Novartis$33
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$29
  • Tarsus Pharmaceuticals, Inc.$18
  • plus $16 from 1 others

What the payments were for

  • Speaking & faculty fees$1,50057%
  • Travel & lodging$54621%
  • Food & beverage$59423%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,641 in reported general payments places this provider in the 85th percentile of 867 optometrist providers in Wisconsin.

See all optometrist providers in Wisconsin

Medicare billing

Part B allowed, 2024
$60,028
Medicare patients
260
Services billed
3,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner36$65,209
RestasisCyclosporine25$14,948
VyzultaLatanoprostene Bunod20$9,663
Loteprednol Etabonate25$3,685
Latanoprost202$2,081
Bimatoprost21$1,978
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$1,717
Prednisolone Acetate25$757
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat23$546
Timolol Maleate46$303
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha15$176
Brimonidine Tartrate13$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$18$65,20936 claims
Bausch & Lomb Americas Inc.Vyzulta$54$9,66320 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$29$3,68525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 867 optometrist providers in Wisconsin.

Other optometrist in Waupaca

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →